ApDC
Aptamer Drug Conjugates: A Novel Targeted Delivery Platform for Oncology
ApDCs
Targeted therapy modality in which aptamers replace mAbs in drug conjugates
Have target specificity and affinity on par with mAbs
Can be selected for inhibitory, stimulatory, or no biological activity
Support receptor-mediated internalization
Different aptamers may be joined to form bi-specific therapeutic agents
ApDC payload can be tailored to suit therapeutic strategy:
Immunostimulant
RNAi, ASO, miRNA, etc.
ApDCs offer significant CMC advantages over ADC
CMC Advantages of ApDC vs. ADC
Immuno-stimulatory oliogonucleotides (e.g., CpG sequences) can be directly synthesized as chimeric extension of targeting aptamer sequence
Streamlined manufacturing/analytical chemistry approach
Lower COGS
Shortened CMC development lead times
Chemotherapeutic toxin payload conjugation chemistry is simplified
Site-specific conjugation using NHS-, thiol or Click chemistry
Constant 1:1 stoichiometry of targeting and payload moieties
On equimolar basis, more payload for ApDC than ADC
MW of aptamer is between 10,000 to 15,000
Contact
© 2025 Guardian Therapeutics. All rights reserved.
Headquarters
Guardian Therapeutics
600 Suffolk St.
Suite 250
Lowell, MA 01854
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com